Tranexamic Acid in Intertrochanteric and Subtrochanteric Femur Fractures

Status unconfirmed · Phase 4 · Has a placebo group

Conditions studied: Hip Fractures, Surgical Blood Loss

In brief

The objective of this study is to evaluate the effect of Tranexamic Acid (TXA) on blood loss and need for perioperative blood transfusion following intertrochanteric and subtrochanteric femur fractures. TXA is a antifibrinolytic medication that prevents the breakdown of blood clots by inhibiting the activation of plasminogen to plasmin in the coagulation cascade. Our hypothesis is that by providing TXA at the time of hospital admission it will decrease the amount of preoperative and intraoperative bleeding thereby leading to a decreased need for post-operative transfusion. This a double blinded, placebo controlled, therapeutic trial in which half of patients will be randomized to receive TXA at the time of hospital admission and half of patients will receive a placebo.

Key facts

Study ID
NCT02580227
Run by
Good Samaritan Regional Medical Center, Oregon
People needed
100
Starts
2015-06-01
Expected to finish
2017-03-01
Last updated by the study team
2015-10-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.